Nothing Special   »   [go: up one dir, main page]

CA2539214A1 - Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides - Google Patents

Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides Download PDF

Info

Publication number
CA2539214A1
CA2539214A1 CA002539214A CA2539214A CA2539214A1 CA 2539214 A1 CA2539214 A1 CA 2539214A1 CA 002539214 A CA002539214 A CA 002539214A CA 2539214 A CA2539214 A CA 2539214A CA 2539214 A1 CA2539214 A1 CA 2539214A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
sequence
shows
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002539214A
Other languages
English (en)
Inventor
Kevin P. Baker
Jian Chen
Luc Desnoyers
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
James Pan
Victoria Smith
Colin K. Watanabe
William I. Wood
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/005601 external-priority patent/WO2000056889A2/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/013705 external-priority patent/WO2000073445A2/fr
Priority claimed from PCT/US2000/014042 external-priority patent/WO2000077037A2/fr
Priority claimed from PCT/US2000/014941 external-priority patent/WO2000073348A2/fr
Priority claimed from PCT/US2000/015264 external-priority patent/WO2000073452A2/fr
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/fr
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/fr
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/fr
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2539214A1 publication Critical patent/CA2539214A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70532B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002539214A 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides Abandoned CA2539214A1 (fr)

Applications Claiming Priority (80)

Application Number Priority Date Filing Date Title
USPCT/US00/05601 2000-03-01
PCT/US2000/005601 WO2000056889A2 (fr) 1999-03-23 2000-03-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
USPCT/US00/05841 2000-03-02
US18720200P 2000-03-03 2000-03-03
US60/187,202 2000-03-03
US18696800P 2000-03-06 2000-03-06
US60/186,968 2000-03-06
US18932000P 2000-03-14 2000-03-14
US18932800P 2000-03-14 2000-03-14
US60/189,328 2000-03-14
US60/189,320 2000-03-14
PCT/US2000/006884 WO2001005972A1 (fr) 1999-07-20 2000-03-15 Compositions et methodes pour traiter des maladies d'ordre immunologique
USPCT/US00/06884 2000-03-15
US19131400P 2000-03-21 2000-03-21
US19082800P 2000-03-21 2000-03-21
US19100700P 2000-03-21 2000-03-21
US19104800P 2000-03-21 2000-03-21
US60/191,314 2000-03-21
US60/191,048 2000-03-21
US60/191,007 2000-03-21
US60/190,828 2000-03-21
US19265500P 2000-03-28 2000-03-28
US60/192,655 2000-03-28
US19303200P 2000-03-29 2000-03-29
US19305300P 2000-03-29 2000-03-29
US60/193,053 2000-03-29
US60/193,032 2000-03-29
USPCT/US00/08439 2000-03-30
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
US19444900P 2000-04-04 2000-04-04
US19464700P 2000-04-04 2000-04-04
US60/194,647 2000-04-04
US60/194,449 2000-04-04
US19600000P 2000-04-11 2000-04-11
US19669000P 2000-04-11 2000-04-11
US19618700P 2000-04-11 2000-04-11
US19597500P 2000-04-11 2000-04-11
US19682000P 2000-04-11 2000-04-11
US60/196,690 2000-04-11
US60/196,000 2000-04-11
US60/196,820 2000-04-11
US60/195,975 2000-04-11
US60/196,187 2000-04-11
US19812100P 2000-04-18 2000-04-18
US19858500P 2000-04-18 2000-04-18
US60/198,121 2000-04-18
US60/198,585 2000-04-18
US19965400P 2000-04-25 2000-04-25
US19955000P 2000-04-25 2000-04-25
US19939700P 2000-04-25 2000-04-25
US60/199,550 2000-04-25
US60/199,397 2000-04-25
US60/199,654 2000-04-25
US20151600P 2000-05-03 2000-05-03
US60/201,516 2000-05-03
USPCT/US00/13705 2000-05-17
PCT/US2000/013705 WO2000073445A2 (fr) 1999-06-02 2000-05-17 Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
USPCT/US00/14042 2000-05-22
PCT/US2000/014042 WO2000077037A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
USPCT/US00/14941 2000-05-30
PCT/US2000/014941 WO2000073348A2 (fr) 1999-06-02 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
USPCT/US00/15264 2000-06-02
PCT/US2000/015264 WO2000073452A2 (fr) 1999-06-02 2000-06-02 Compositions et methodes de traitement de maladies liees a l'immunite
US20983200P 2000-06-05 2000-06-05
US60/209,832 2000-06-05
USPCT/US00/20710 2000-07-28
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
US64484800A 2000-08-22 2000-08-22
US09/644,848 2000-08-22
USPCT/US00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US60/000,000 2000-09-15
USPCT/US00/30952 2000-11-08
PCT/US2000/030952 WO2001049715A2 (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
PCT/US2000/032678 WO2001040466A2 (fr) 1999-12-01 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
USPCT/US00/32678 2000-12-01
PCT/US2000/034956 WO2001046420A2 (fr) 1999-12-23 2000-12-20 Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
USPCT/US00/34956 2000-12-20
CA002401448A CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002401448A Division CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Publications (1)

Publication Number Publication Date
CA2539214A1 true CA2539214A1 (fr) 2001-09-20

Family

ID=40231083

Family Applications (10)

Application Number Title Priority Date Filing Date
CA002533831A Abandoned CA2533831A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534186A Abandoned CA2534186A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533903A Abandoned CA2533903A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534391A Abandoned CA2534391A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534030A Abandoned CA2534030A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002531917A Abandoned CA2531917A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002401448A Abandoned CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534018A Abandoned CA2534018A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002539214A Abandoned CA2539214A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533991A Abandoned CA2533991A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides

Family Applications Before (8)

Application Number Title Priority Date Filing Date
CA002533831A Abandoned CA2533831A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534186A Abandoned CA2534186A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533903A Abandoned CA2533903A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534391A Abandoned CA2534391A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534030A Abandoned CA2534030A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002531917A Abandoned CA2531917A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002401448A Abandoned CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534018A Abandoned CA2534018A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002533991A Abandoned CA2533991A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides

Country Status (5)

Country Link
EP (1) EP1259614A2 (fr)
JP (3) JP2004508805A (fr)
AU (2) AU6802801A (fr)
CA (10) CA2533831A1 (fr)
WO (1) WO2001068848A2 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
CA2301796A1 (fr) 1997-08-19 1999-02-25 Human Genome Sciences, Inc. 70 proteines secretees humaines
AU9386398A (en) 1997-09-12 1999-03-29 Biogen, Inc. Cysteine rich receptors: trail
WO1999014240A1 (fr) * 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Proteine de type recepteur d'interleukine 17
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US20030039648A1 (en) 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030130182A1 (en) * 1997-11-05 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
EP2333069A3 (fr) 1998-05-15 2011-09-14 Genentech, Inc. Utilisations therapeutiques de polypeptides homologues de il-17
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US8133734B2 (en) 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
KR101018134B1 (ko) * 1999-05-13 2011-02-25 쉐링 코포레이션 Ox2 수용체 동족체
EP1623993A3 (fr) * 1999-09-01 2006-06-07 Genetech, Inc. Protéines sécrétées et transmembranaire et acides nucléiques les codant
KR20020056923A (ko) 1999-11-18 2002-07-10 코르바스 인터내셔날, 인코포레이티드 엔도텔리아제를 암호화하는 핵산, 엔도텔리아제 및 이의용도
EP2258848B1 (fr) * 1999-12-23 2014-03-05 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
WO2001083781A2 (fr) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, un nouveau membre dans la famille de la trypsine humaine et son utilisation
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1292619B1 (fr) 2000-06-06 2008-02-06 Bristol-Myers Squibb Company Acides nucleiques et polypeptides apparentes a b7 utiles pour effectuer une immunomodulation
AU2001268440A1 (en) * 2000-06-15 2002-01-08 Millennium Pharmaceuticals, Inc. 53320, a human acyltransferase and uses therefor
NZ535481A (en) * 2000-06-22 2008-04-30 Biogen Idec Inc Polynucleotides encoding GP354 or biologically active portions thereof suitable for use as primers or hybridization probes for the detection of GP354-encoding polynucleotides
JP2004502417A (ja) * 2000-06-30 2004-01-29 アムジェン インコーポレーテッド B7様分子およびその使用
EP1307557A2 (fr) 2000-08-02 2003-05-07 The Johns Hopkins University Profils d'expression de cellules endotheliales
CA2420392A1 (fr) * 2000-08-28 2002-03-07 Human Genome Sciences, Inc. 17 proteines humaines secretees
WO2002020800A2 (fr) * 2000-09-01 2002-03-14 Millennium Pharmaceuticals, Inc. Kinases 16658, 14223, et 16002, et utilisations
AU2001294703A1 (en) * 2000-09-25 2002-04-08 Millennium Pharmaceuticals, Inc. 32624 a novel human udp-glucuronosyl and glycosyl transferase family member and uses thereof
JP2004535758A (ja) 2000-11-14 2004-12-02 ブリストル−マイヤーズ スクイブ カンパニー リンパ様細胞lsi−01から分泌される新規なヒトセルピンをコードするポリヌクレオチド
DE10106835A1 (de) * 2001-02-14 2002-09-05 Basf Lynx Bioscience Ag Signaltransduktionsproteine 15B3, 15B3-1 und 15B3-2 und zugrundeliegende DNA-Sequenzen
JPWO2002064769A1 (ja) * 2001-02-15 2004-06-17 塩野義製薬株式会社 新規疾患マーカー
EP1873245A1 (fr) * 2001-02-28 2008-01-02 Genentech, Inc. Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
JP2004533222A (ja) * 2001-03-12 2004-11-04 インサイト・ゲノミックス・インコーポレイテッド 免疫グロブリンスーパーファミリータンパク質
CA2443123A1 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
WO2002083856A2 (fr) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Polynucleotides codant deux nouveaux recepteurs couples aux proteines g, hgprbmy28 et hgprbmy29, et leurs variants d'epissage
US7125663B2 (en) 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
JP4224395B2 (ja) * 2001-06-22 2009-02-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド PanCAM核酸およびポリペプチド
WO2003004530A1 (fr) * 2001-07-06 2003-01-16 Bayer Aktiengesellschaft Régulation de la protéine semblable à un récepteur de la somatostatine humaine
CA2453653A1 (fr) * 2001-07-26 2003-02-06 Genset S.A. Polynucleotides et polypeptides gmg-2 et leurs utilisations
JP4702819B2 (ja) 2001-08-01 2011-06-15 生化学工業株式会社 コンドロイチン合成酵素
WO2003018805A1 (fr) * 2001-08-23 2003-03-06 Japan Science And Technology Agency Regulateurs de la proliferation de cellules souches hematopoietiques et polynucleotides codant ces regulateurs
EP2153843B1 (fr) * 2001-09-18 2012-08-15 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic d'une tumeur
AU2002333862A1 (en) * 2001-09-20 2003-04-01 Bayer Aktiengesellschaft Regulation of human prolyl 4-hydroxylase alpha subunit precursor
CA2466138A1 (fr) * 2001-11-02 2003-05-15 Shen Wu Wang Antigene specifique du lymphome des lymphocytes b destine a etre utilise dans le diagnostic et le traitement des malignites des lymphocytes b
WO2003054164A2 (fr) * 2001-12-19 2003-07-03 Immunex Corporation Polypeptide de lectine de type c, polynucleotide et procedes de fabrication et d'utilisation correspondant
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
MXPA04010091A (es) * 2002-04-17 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
EP1507553A2 (fr) 2002-05-29 2005-02-23 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteines specifiques du pancreas
US20070009515A1 (en) * 2002-05-31 2007-01-11 Hidetoshi Inoko Inflammatory skin disease-related slurp-2 gene and utilization thereof
WO2003102193A1 (fr) * 2002-05-31 2003-12-11 Seikagaku Corporation Chondroitine synthetase et acide nucleique codant pour cette enzyme
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
DE10242016A1 (de) * 2002-09-11 2004-03-25 Esplora GmbH c/o TU Darmstadt Institut für Biochemie Verfahren zur Identifizierung BHS-spezifischer Proteine und Fragmente davon
AU2003267097B2 (en) * 2002-09-11 2009-09-17 Genentech, Inc. Novel composition and methods for the treatment of psoriasis
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
KR20050085881A (ko) * 2002-12-26 2005-08-29 다케다 야쿠힌 고교 가부시키가이샤 신규 단백질 및 그 용도
WO2004063226A2 (fr) * 2002-12-27 2004-07-29 Applied Research Systems Ars Holding N.V. Nouveaux polypeptides de type fibrilline
JP2006518193A (ja) * 2003-01-16 2006-08-10 ユニバーシティ オブ バージニア パテント ファウンデーション 精子特異的リゾチーム様タンパク質
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
JP5340537B2 (ja) 2003-07-08 2013-11-13 ジェネンテック, インコーポレイテッド Il−17異種ポリペプチドとその治療上の用途
CA2535859A1 (fr) 2003-08-14 2005-03-03 Dyax Corp. Ligands de l'endotheliase-2
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
JPWO2005061704A1 (ja) * 2003-12-24 2007-07-12 武田薬品工業株式会社 癌の予防・治療剤
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2005270078A1 (en) 2004-07-02 2006-02-09 Genentech, Inc. Compositions and methods for treatment of non-hodgkin's lymphoma
EP1789070B1 (fr) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Influence du taj sur les fonctions neuronales
AU2005267722B2 (en) 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
US7544659B2 (en) 2004-08-13 2009-06-09 Genentech, Inc. Promotion of axonal regeneration
EP1863340A2 (fr) * 2005-03-11 2007-12-12 Genentech, Inc. Disruptions geniques, compositions et methodes afferentes
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
WO2007067991A2 (fr) 2005-12-08 2007-06-14 Medarex, Inc. Anticorps monoclonaux humains se fixant a l'o8e
WO2007107774A2 (fr) * 2006-03-22 2007-09-27 Cartela R & D Ab Nouvelles méthodes de diagnostic et de traitement
CA2649387A1 (fr) * 2006-04-19 2008-03-27 Genentech, Inc. Nouvelles disruptions genetiques, compositions et procedes les concernant
WO2008019351A2 (fr) 2006-08-04 2008-02-14 Isis Pharmaceuticals, Inc. Compositions et leurs utilisations dirigées sur la diacylglycérol acyltransférase 1
WO2008026010A1 (fr) 2006-08-29 2008-03-06 Oxford Genome Sciences (Uk) Ltd Identification d'une protéine associée à un carcinome hépatocellulaire, à un glioblastome et à un cancer du poumon
US8058014B2 (en) 2006-09-29 2011-11-15 University Of Maryland, Baltimore Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2
RU2474588C2 (ru) 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
EP2300034B1 (fr) * 2008-06-02 2018-08-08 Dana-Farber Cancer Institute, Inc. Composition pharmaceutique destinée à être utilisée pour le traitement ou la prévention du myélome multiple ou de la macroglobulinémie de waldenström
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. Cadm1に特異的な完全ヒト抗体
AU2010244142B2 (en) 2009-05-05 2016-07-21 Novimmune Sa Anti-IL-17F antibodies and methods of use thereof
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014071402A1 (fr) 2012-11-05 2014-05-08 Dana-Farber Cancer Institute, Inc. Xbp1, cd138 et cs1, compositions pharmaceutiques qui comprennent les peptides et procédés d'utilisation de tels peptides et compositions
WO2014075788A1 (fr) 2012-11-13 2014-05-22 Biontech Ag Agents de traitement de maladies cancéreuses exprimant claudine
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
PE20180800A1 (es) 2015-07-10 2018-05-09 Ionis Pharmaceuticals Inc Moduladores de diaciglicerol aciltransferasa 2 (dgat2)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19817948A1 (de) * 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Endometrium-Tumor
CA2328895A1 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
AU3774500A (en) * 1999-03-31 2000-10-16 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; "orfx"
CA2383254A1 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
WO2001040269A2 (fr) * 1999-11-30 2001-06-07 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
CA2399776A1 (fr) * 2000-02-03 2001-08-09 Hyseq, Inc. Acides nucleiques et polypeptides
JP2004520806A (ja) * 2000-08-24 2004-07-15 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法

Also Published As

Publication number Publication date
CA2533991A1 (fr) 2001-09-20
CA2534018A1 (fr) 2001-09-20
CA2534186A1 (fr) 2001-09-20
CA2534030A1 (fr) 2001-09-20
CA2534391A1 (fr) 2001-09-20
CA2533903A1 (fr) 2001-09-20
AU6802801A (en) 2001-09-24
CA2533831A1 (fr) 2001-09-20
JP2006081548A (ja) 2006-03-30
CA2401448A1 (fr) 2001-09-20
EP1259614A2 (fr) 2002-11-27
WO2001068848A2 (fr) 2001-09-20
CA2531917A1 (fr) 2001-09-20
JP2004508805A (ja) 2004-03-25
JP2008301822A (ja) 2008-12-18
AU2001268028A1 (en) 2001-09-24
WO2001068848A3 (fr) 2002-08-29

Similar Documents

Publication Publication Date Title
US7189838B2 (en) PRO9834 nucleic acids
US7087421B2 (en) Pro1278 polypeptides
CA2539214A1 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US20030166104A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7084255B2 (en) PRO1278 polypeptides
US20040023321A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104548A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104547A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104551A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead